BillionToOne (BLLN) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $5.44B, a trailing price-to-earnings ratio of 60.0 and a free-cash-flow yield of 0.7%. Nama's AI scorecard rates it Buy, 6.2 out of 10.
AI scorecard
Buy · 6.2/10
Positive, at the low end of Buy. As of Nov 7, 2026.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-24.3%
How far the last close sits under the highest price of the past five years.
Market cap
$5.44B
Trailing P/E
60.0
Price / book
9.9
Price / sales
13.5
FCF yield
0.7%
Dividend yield
—
Gross margin
71.3%
Operating margin
10.9%
Net margin
9.5%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
—
Exchange
NASDAQ
Sector
Healthcare
Industry
Diagnostics Research
BLLN earnings
Next report: Mar 3, 2027 (Q4 2026, EPS estimate $0.30).
Beat the EPS estimate in 3 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 4, 2026
$0.48
$0.30
+60.0%
$122.98M
Q2 2026
Aug 5, 2026
$0.36
$0.16
+125.0%
$109.45M
Q4 2025
Mar 4, 2026
$0.15
$0.17
-11.8%
$96.05M
Q3 2025
Dec 9, 2025
$0.91
$0.16
+468.8%
$83.52M
BLLN analyst price target
Median target $130.00 from 7 analysts, ranging $110.00 – $145.00.
Nama's AI scorecard currently rates BillionToOne Buy (6.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is BLLN's P/E ratio?
BillionToOne trades at a trailing price-to-earnings ratio of 60.0.
When does BLLN report earnings?
BillionToOne's next scheduled report is on Mar 3, 2027. Analysts expect EPS of $0.30.
What is the BLLN price target?
The median analyst price target from 7 analysts is $130.00, with a range of $110.00 – $145.00.
Is BLLN Shariah compliant?
Nama's AAOIFI-style screen reads BillionToOne as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.